ESTRO 36 Abstract Book

764 / 1096

S748 ESTRO 36
_______________________________________________________________________________________________
was in breast, lung, colorectal and kidney. Performance
status of patients was 0-1 according ECOG-scale. All
patients have previously radically treated primary tumor
and no more than 3-4 distant metastatic lesion by the
moment of treatment. Patients receive radiosurgery or
hypofractined irradiation in a single dose 6-20 Gy and total
summary dose 20-60 Gy by using CyberKhife system.
Results
In 31 patients with distant metastases in brain, lung, liver,
renal and epinephrine after local ablative radiosurgery we
registered full tumor regression during 2-6 years. The
existence of this group of patients clinically confirms
molecular differences between higher and low metastatic
potential tumors. That is why previously shown genetic
features of oligometastatic tumors change our ideas about
possibilities of active local treatment in cases of
metastatic disease.
Conclusion
Thus, our observations clinically confirm the existence of
group of patients with oligometastatic tumor disease
caused by specific genomic changes in tumor cells. In such
cases, local ablative radiosurgery with precision and high
doses of radiation could be curative.
EP-1399 Rotary-Dual Total Skin Electron Beam Therapy
as palliative treatment for mycosis fungoides
A. Jodda1, M. Pawlaczyk2, M. Fundowicz3, T. Piotrowski4
1 Greater Poland Cancer Centre, Medical Physics, Poznan,
Poland
2 Poznan University of Medical Sciences, Skin Diseases
Prevention, Poznan, Poland
3 Greater Poland Cancer Centre, Radiotherapy, Poznan,
Poland
4 Poznan University of Medical Sciences, Electroradiology,
Poznan, Poland
Purpose or Objective
To retrospectively assess the efficacy and toxicity of a
total skin electron beam therapy (TSEBT) in patients with
primary cutaneous T-cell lymphoma at various stages of
development.
Material and Methods
Treatment results of 40 patients (8 female, 32 male) in
median age 60 years (from 40-84 years), with primary
cutaneous T-cell lymphoma (mycosis fungoides), stage IB-
III, treated between 2001 and 2013 were reviewed. All
patients were symptomatic. The median total dose was
32Gy (range 12-40Gy), applied with 1,5 Gy per day four
times weekly for the whole skin.
Results
The median follow-up was 60 months. A clinical complete
response was documented in 29 (72.5%) and a partial
response in 11 patients (27.5%). The clinical response
significantly influenced on the overall survival (OS)
(p=0.002) and progression-free survival (PFS) (p<0.001).
The mean OS was 76 months. The mean PFS was 48.9
months and the actuarial one-, two- year PFS were 67.5%,
55%. The statistically significant correlation was found
between partial and total remission time and the stages
of lymphoma (p=0.015). The side effects were observed in
all patients during the treatment and include: erythema,
skin dryness and desquamation, pruritus, onycholysis and
alopecia.
Conclusion
For palliation of symptomatic cutaneous lymphoma, total
skin electron beam therapy is well tolerated and an
efficient treatment.
EP-1400 Quality of Life in Responders after Palliative
Radiation Therapy for Painful Bone Metastases
L.C. Mendez1, J.L. Padilha2, K.M. Lima 3, E. Chow1, F.Y.
Moraes 4, M.D.P.E. Esteves5, M.F. Silva2, G.N. Marta6,7
1 Sunnybrook Odette Cancer Centre- University of
Toronto-, Radiation Oncology, Toronto, Canada
2Universidade Federal de Santa Maria, Radiation
Oncology, Santa Maria, Brazil
3Faculdade de Medicina da Universidade de São Paulo,
Radiation Oncology, Sao Paulo, Brazil
4Princess Margaret Cancer - University of Toronto,
Radiation Oncology, Sao Paulo, Canada
5Instituto do Câncer do Estado de São Paulo ICESP -
Faculdade de Medicina da Universidade de São Paulo,
Clinical Oncology, Sao Paulo, Brazil
6Hospital Sírio-Libanês, Radiation Oncology, São Paulo,
Brazil
7Instituto do Câncer do Estado de São Paulo ICESP -
Faculdade de Medicina da Universidade de São Paulo,
Radiation Oncology, Sao Paulo, Brazil
Purpose or Objective
Bone metastases cause pain, suffering and impaired
quality of life (QOL). Palliative radiotherapy (RT) is an
effective method in controlling pain, reducing analgesics
use and improving QOL. This study goal was to investigate
the changes in QOL scores among patients who responded
to RT.
Material and Methods
A prospective study evaluating the role of radiation
therapy in a public hospital in São Paulo-Brazil recorded
patients’ opioid use, pain score, Portuguese version of
QLQ-BM22 and QLQ-C30 before and 2 months after
radiotherapy. Analgesic use and pain score were used to
calculate international pain response category. Overall
response was defined as the sum of complete response
(CR) and partial response (PR). CR was defined as pain
score of 0 with no increase in analgesic intake whereas PR
was defined as pain reduction ≥ 2 without analgesic
increase or analgesic reduction in ≥25% without increase
in pain at the treated site.
Results
From September 2014 to October 2015, 25 patients with
bone metastases responded to RT (1 CR, 24PR). There
were 8 male and 17 female patients. The median age and
ECOG of the 25 patients was 57 years old (range 22 to 89)
and 2 (range 0 to 3), respectively. Patient’s primary
cancer site was breast (11), prostate (5), lung (2), others
(7). For QLQ-BM 22, the mean scores of 4 categories at
baseline were: Pain site (PS) 39, Pain characteristics (PC)
61, Function Interference (FI) 49 and Psycho-social aspects
(PA) 57. At 2 month follow up, the scores were PS 27, PC
37, FI 70 and PA 59. Statistical significant improvement
(p<0.05) was seen in PS, PC, FI but not PA. In the QLQ-
C30, the mean scores were not statistically different for
all categories, except for pain that demonstrated a 29
point decrease in the pain score domain (69 to 40).
Conclusion
Responders to RT at 2 month presented improvement in
BM22 and C30 pain domains, and also improvement in
functional interference if BM22 questionnaire. Patients
with painful bone metastases may receive palliative
radiation therapy to improve both pain and QOL.
EP-1401 SBRT for solitary extracranial metastases from
gynecologic malignancies
M.C. Repka1, N. Aghdam1, S. Suy1, S.P. Collins 1, W.
Barnes 2, B.T. Collins1
1Georgetown University Hospital, Department of
Radiation Medicine, Washington, USA
2Georgetown University Hospital, Division of Gynecologic
Oncology, Washington, USA
Purpose or Objective
Solitary extracranial metastases from gynecologic
malignancies have historically been treated with either
surgery or conventional radiation therapy. We report
mature local control, toxicity, and survival for patients